Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does red meat consumption impact lipitor's side effects?Can lipitor's nerve damage recovery be sped up using only natural methods?Does regular stretching impact lipitor's efficacy?Atorvastatin and grapefruit interaction?What non statin drugs best replace lipitor's liver impact?
See the DrugPatentWatch profile for Inlyta
Key Differences Between Inlyta and Keytruda Inlyta (axitinib) and Keytruda (pembrolizumab) are two cancer medications developed and marketed by different companies. While both drugs are used to treat various types of cancer, they belong to distinct classes and have different mechanisms of action [1]. Differences in Mechanism of Action Inlyta is a tyrosine kinase inhibitor, specifically targeting the vascular endothelial growth factor receptors (VEGFRs), which play a key role in angiogenesis (formation of new blood vessels) and tumor growth [2]. Keytruda, on the other hand, is a programmed death receptor-1 (PD-1) inhibitor, which works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells that display PD-L1 on their surface [3]. Uses and Indications Inlyta is primarily used to treat renal cell carcinoma (RCC), a type of kidney cancer, as well as advanced or metastatic thyroid cancer. Keytruda, in contrast, is approved for a broader range of cancers, including RCC, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and others [4]. Efficacy and Side Effects Clinical trials and real-world studies have shown varying levels of efficacy and tolerability between Inlyta and Keytruda. Inlyta has demonstrated significant improvements in progression-free survival (PFS) in RCC patients, while Keytruda has shown impressive overall response rates in various cancer types. Side effects vary between the two drugs, with Inlyta causing more gastrointestinal issues and Keytruda causing more skin and skin cancer-related symptoms [5]. Patent and Exclusivity Inlyta's patents expire in 2024, allowing generic competitors to enter the market [6]. Keytruda's patent will expire in 2028, but its exclusivity may be extended due to ongoing clinical trials and regulatory reviews [7]. Sources: 1. National Cancer Institute - Inlyta and Keytruda fact sheets 2. European Society of Medical Oncology - Inlyta mechanism of action 3. National Institute of Mental Health - Immunotherapy for Cancer fact sheet 4. FDA.gov - Keytruda approvals and indications 5. CancerNetwork - Inlyta vs. Keytruda comparisons 6. DrugPatentWatch.com - Inlyta patent expiration 7. Bloomberg Law - Keytruda patent extension
Other Questions About Inlyta :